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Objective: Adverse drug events (ADEs) are drug-related events which continue to pose serious 
challenges to the safety of patients. There are a number of ways to monitor ADEs, and the use of 
indictors to screen them provides an alternative method for detecting them. This method helps 
to assess the safety of drugs by the manual record review technique. The aim of this work was 
to develop a list of indicators to use in medical units of the study hospital to identify ADEs.
Setting: Tertiary care teaching hospital in India.
Method: An initial list of ADE indicators based on published literature was developed by a 
panel of three experts. The list of indicators was subjected to review by a Delphi panel of five 
members. The Delphi panel reviewed the list of valid indicators and also suggested an addition of 
new indicators. The final list of indicators was used to review 100 previously documented ADE 
case reports. The case reports were screened for the presence of any of the indicators from the list. 
Parameters studied included number of indicators per case report and the most used indicators.
Results: From the literature, a 72 item indicator list was initially prepared which was further 
narrowed down to a list of 63 items. The Delphi panel conducted a review with these 63 items. 
At the end of review, and after addition and deletion of indicators, a 49 item indicator list was 
finalized. When this list of indicators was used for the review of ADE case reports, 42 indicators 
were identified. On average, three indicators were present in the reviewed case reports.
Conclusion: An indicator list was developed for identification of ADEs in the study setup. 
The relevance of this indicator list was demonstrated by the presence of these indicators in the 
previously documented ADE reports. This is the first study from India to report on the devel-
opment of ADE indicators, which might provide an alternative method to detecting ADEs in 
the setup of future studies.
Keywords: adverse drug events, drug safety indicators, Delphi panel
Introduction
An adverse drug event (ADE) is defined as “an injury resulting from medical inter-
vention related to drugs”.1 ADEs continues to be a serious challenge for the safety of 
patients. A significant number of ADEs are preventable in nature, and therefore this 
represents an avoidable burden on health care.2 ADEs are monitored in a clinical setup 
using a number of methods like case reports, spontaneous reporting systems, intensive 
event recording, case-control studies, case-cohort studies, prospective cohort studies, 
incident reports, retrospective or concurrent chart reviews and observational studies.3–5 
Each methodology has its own advantages and disadvantages.6
An indicator is a clue that helps a health care organization to identify adverse 
events and assess the overall harm that occurs from medical care within that orga-
nization.7 This methodology is based on identifying and addressing errors that are Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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highly associated with negative outcomes.8,9 Indicators offer 
an approach to standardizing error identification that may 
provide more consistent and accurate information than tradi-
tional error reporting systems.10 This system was also used for 
identification of adverse events along with traditional chart 
audits, incident reporting, or voluntary reporting. There are 
a number of reports on implementing electronic triggers to 
screen hospital records for the occurrence of ADEs.11,12
India is a developing country which is a member of the 
World Health Organization-run pharmacovigilance program. 
The pharmacovigilance in this country is still in its infancy.13 
ADE monitoring is carried out sporadically, and studies have 
reported that under-reporting is common in many of the study 
sites.14–16 This study was carried out in a tertiary care teaching 
hospital in South India. The ADE monitoring program was 
initiated in the current setup around a decade ago, but the 
level of participation of clinicians in this program is low.17 It 
was planned to use indicators to identify ADEs in the current 
setup. For this purpose there was a need to develop a list of 
indicators specific for this setup. The present work was aimed 
to develop an indicator list based on available literature and 
modify it suitably with the help of a Delphi panel review 
and review of adverse event case reports.
Methodology
Development of indicators list
An initial list of ADE indicators was prepared based on pub-
lished literature.7,18–23 These indicators were reviewed by a panel 
of three experts (two clinical pharmacists and a   clinician). The 
indicators which were relevant to the study setup were selected. 
The indicators relevant to general medical practice were kept in 
the list, whereas the indicators related to other specialties like 
psychiatry, intensive care unit (ICU), and surgery, were deleted. 
The review team collectively decided on whether to keep or 
delete a particular indicator from the list. This exercise was 
carried out to condense the list, so that the Delphi panel could 
work on it for the development of a final set of indicators.
Delphi panel review
A Delphi panel was formed with three clinicians and two 
clinical pharmacists. The members evaluated the indicator list 
anonymously and scored it. The panel members rated each item 
on the list on a Likert scale which represented a score from 
1 to 5. During this review panel members were asked to sug-
gest any additional indicators which could be added to the list. 
At the end of the first review, the scores were   summarized and 
this was presented to the panel members along with their own 
scores. In the second review, panel members were encouraged to 
  reassess their opinion in light of scores given by other members. 
  Additional indicators were added to the list for review. After the 
second review, the mean score for each item was calculated. The 
mean score of 3 and above, out of 5, was considered as criteria 
for inclusion into the list. For the newly added indicators, one 
more review was conducted and mean scores were calculated. 
The final comprehensive list was divided into four categories, 
namely: (1) abnormal changes in clinical condition, (2) changes 
in patient care process, (3) drug-related alterations, (4) changes 
in lab investigations. (Tables 1–4)
After the preparation of a comprehensive list of indicators, 
they were used to screen previously identified and documented 
ADE case reports. A set of 100 previously documented ADE 
reports were randomly picked from the documented database. 
These adverse events were identified by clinical pharmacists 
from medicine wards during their rounds with clinicians. These 
reports contain complete details of the case which included 
medical history, diagnosis, lab investigations, therapy and 
ADE. Reports were reviewed for the presence of any indicators 
from the prepared list. The following four factors were then 
assessed: mean number of indicators per case report, commonly 
identified indicators, total number of identified indicators, and 
indicators that were not identified in any of the case reports.
Results
Screening by expert panel
From the literature, 72 indicators were selected for the list. 
The expert panel conducted a review of indicators. Items 
were added to the list based on the relevance of indicators for 
the internal medicine department and the utility of specific 
indicators. Indicators like ‘hospital visit due to depression 
or other psychiatric illness due to drug treatment or lack 
of   monitoring’ was removed since such cases are usually 
presented to the psychiatry department and do not come 
under the general medicine department. Specific indicators 
like theophylline toxicity were removed because the use of 
theophylline is less common and its monitoring is not carried 
out. Indicators like toxicity of individual antiepileptic drugs 
such as phenytoin, carbamazepine, and sodium valproate were 
combined as ‘drug toxicity’. An indicator on long term use of 
codeine and acetaminophen for pain relief resulting in broken 
bones was removed since such a practice of using codeine for 
pain relief is not common in this setup. Indicators on gastritis 
and upper intestinal bleeding due to many different drugs and 
factors were reduced to two indicators. Many indicators were 
recommended to be deleted since their prevalence was thought 
to be low for this setup. Some indicators were combined with 
others since they were similar. At the end of the review, the 
list was modified to include 63 indicators.Drug, Healthcare and Patient Safety 2010:2
Table 1 Indicators of abnormal change in clinical condition of patients
Indicators Cause
Headache  Drug induced 
Over-sedation/lethargy/hypotension Medication-related ADe
Immobility (emboli) Low molecular heparin
Bleeding Use of warfarin without monitoring InR during initiation and follow-up of therapy. 
Concurrent use of warfarin and an oral/topical nSAID/antibiotic/ACe inhibitors/
amiodarone without monitoring the InR within 10 days. 
Diarrhea/use of antidiarrheal  Antibiotics
Dyspepsia or upper GI bleed or perforation or GI ulcer  
or anemia/use of PPIs
Use of a beta-blocker/oral or topical nSAIDs/oral corticosteroids in a patient with 
a PMH or current diagnosis of peptic ulcers and/or GI bleeding. Additional reliability 
indicator. Use of more than one nSAID for more than two weeks without 
protective agents like H2 receptor antagonists or PPIs.
GI disturbance or GI bleed Long-term use of ferrous sulphate without monitoring hemoglobin
Melena  Drug induced GI Ulcer
Vomiting, nausea/use of antiemetics Drug induced 
Loss of seizure control or seizure activity Use of lamotrigine/carbamazepine/phenytoin/valproic acid without drug level 
monitoring at least every 6 months. Use of antibiotics.
Tremor  Drug induced 
Acute renal failure and/or renal insufficiency Use of an ACe inhibitor (eg, captopril, enalapril, etc). BUn/serum creatinine not 
done at initiation of therapy and at least every 3 months thereafter. Use of nSAID 
for 3 months. Use of Lithium.
Acute urinary retention Diagnosis/history of bladder atony due to diabetes. Use of imipramine. Diagnosis  
of BPH and use of an anticholinergic agent.
Acute respiratory failure History/diagnosis of severe COPD. Use of a medium- to long- acting 
benzodiazepine.
Asthma exacerbation and/or status asthmaticus and/or  
eR visit/hospitalization due to asthma
Diagnosis of asthma. Use of a bronchodilator. no use of a maintenance 
corticosteroid (eg, beclomethasone, etc).
Hospital visit due to asthma symptoms Use of an inhaled short-acting bronchodilator more than once daily or at night  
in an asthmatic patient with no regular inhaled ‘preventer’ therapy  
(corticosteroid, cromoglicate, or nedocromil)
eR visit/hospitalization due to hyperthyroidism Use of a thyroid or antithyroid agent (eg, levothyroxine, propylthiouracil, etc).  
T4/TSH not done within 6 weeks after initiation of therapy and at least every  
12 months thereafter.
eR visit/hospitalization due to hypothyroidism Lithium use for at least 6 months. TSH not done at least every 6 months.
Oral thrush/dysphonia/oral candidiasis Use of an inhaled steroid by metered dose inhaler without usage of a spacer device
edema  Chronic use of amlodipine 
Skin rashes/angioedema/Steven Johnson syndrome/Ten Drug induced
Pyrexia Drug induced
Abbreviations: GI, gastrointestinal; PPIs, proton pump inhibitors; eR visit, emergency room visit; Ten, toxic epidermal necrolysis; ADe, adverse drug event; InR, 
international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; ACE inhibitors, angiotensin-converting enzyme inhibitors; PMH, postmenopasusal hormone; 
BUn, blood urea nitrogen; BPH, benign prostate hyperplasia; COPD, chronic obstructive pulmonary disease; TSH, thyroid-stimulating hormone.
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Delphi panel review
The Delphi panel reviewed the indicator list for its utility. 
Five reviewers independently reviewed the list and rated them 
on a scale of 1 to 5. At the end of the first review, 22 out of 
63 items in the list were rated less than 3 points and were sub-
sequently eliminated. Eight new indicators were suggested 
by the members of Delphi panel. In the second review a total 
of 71 items were included in the list. The panel members 
were asked to rate all of the items. At the end of the second 
review, a total of 49 indicators received scores above 3. The 
results were again presented to the panel members with their 
scores against the scores of other team members for the third 
review. The third review did not alter the scores, 49 were 
rated above 3 points, and were included in the list.
Assessment of documented adverse 
event reports
A total of 42 indicators were identified in previous ADE 
case reports. Each reviewed case report had an average of 
three indicators from the list. Seven indicators could not 
be   identified in any of the reported case records. Indicators 
which were most frequently identified from the reports 
were studied (Table 5). Abrupt drug withdrawal was the 
most common indicator identified in the reports, followed 
by repeat requests for laboratory tests, and use of anti-
histamine/steroids for the management of drug allergies. 
Drug induced pyrexia, edema, raised serum creatinine, 
and tremors were among the least identified indicators in 
reviewed reports.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Discussion
This report describes the development of ADE indicators in 
the current setup. This study used a team of clinicians and 
pharmacists to review the developed ADE indicators. The 
Delphi technique, which has been used in a number of previ-
ous studies, was used as a method of assessing the developed 
indicator list.
An initial list of 71 indicators selected from the literature 
was considered unmanageable, and after the Delphi panel 
review, the number of indicators was reduced to 49. In a 
study by Matlow et al on the development of trigger tools 
for pediatrics, they reported that 94 indicators were initially 
selected by a review committee. This list was considered as 
not practical for routine use, and was subsequently reduced to 
a manageable list of 40 indicators.19 An indicator list contain-
ing a reasonably limited number of items is preferable since 
it reduces the burden on case record reviewers.
Abrupt withdrawal of drugs was identified most frequently 
as an indicator in the records. Since this is the first step in 
management of any drug-related adverse event, it could be 
found in many of the previously documented adverse event 
reports. Another commonly identified indicator was frequent 
requests for a specific lab investigation. Repeat requests for a 
particular investigation signifies a certain level of complica-
tion in the management of the patient’s condition, and might 
be associated with drug-related adverse events.
The indicator list was classified under four major categories: 
abnormal clinical changes, change in patient care, laboratory 
investigation-related, and drug/antidote-related. Among these 
four classes of indicators abnormal clinical changes included 
22 indicators. This showed the preference of reviewers for the 
indicators which can identify adverse events based on the data 
available from patient progress charts and follow-up. Changes 
in patient care and lab investigations were the other important 
group of indicators considered for identifying ADEs (10 each). 
In contrast to a study published by Handler et al in which the 
medication concentration signals were considered as impor-
tant, abnormal clinical changes were considered as important 
indicators in this study.24 In this study, even when toxicity was 
suspected for a drug, estimation of drug levels was not carried 
Table 2 Indicators of change in patient care process
Indicators Cause
Abrupt withdrawal of medication Any ADe
Intubation/re-intubation Related ADe/drug induced respiratory depress 
eR visit/hospitalization due to congestive heart failure Use of a calcium channel blocker (eg, diltiazem, etc). Use of beta 
blockers. Oral/topical nSAID use for at least 3 months.
Use of blood products Drug induced hematological disorder
eR visit/hospitalization due to extreme hypoglycemia History/diagnosis of diabetes. Use of insulin/oral hypoglycemics.  
Use of a β-adrenergic blocking agent (eg, propranolol, nadolol).  
Use of fluroquinolones.
eR visit/hospitalization due to worsening renal impairment  
and/or acute renal failure and/or renal insufficiency
Diagnosis and/or history of kidney disease. Use of tetracycline.  
Use of a select urinary anti-infective agent (nalidixic acid, 
nitrofurantoin, or methenamine complexes). 
Dose reduction Related ADe
Admission to dialysis unit Drug-induced ARF
emergency visit/admission Drug-induced complications
Readmission to ICU Drug-related/ADe
Abbreviations: ER, emergency room; ICU, intensive care unit; ADE, adverse drug event; NSAID, nonsteroidal anti-inflammatory drug; ARF, acute renal failure.
Table 3 Indicators of drug-related alterations
Indicators Cause
Use of antihistamines Drug allergy
Digoxin toxicity Concurrent use of digoxin and a potassium-sparing diuretic or potassium 
supplements without monitoring digoxin levels. Addition of amiodarone/
verapamil to a patient on digoxin without reducing the digoxin dosage
Vitamin K Bleeding/over usage of anticoagulant 
Use of laxative Drug induced (antibiotics, opioids, amlodipine, amiodarone)
Use of K-bind Potassium toxicity
Aminoglycoside toxicity (acute renal failure and/or renal insufficiency  
and/or vestibular damage and/or auditory damage)
Use of an aminoglycoside. Serum creatinine not done before and after 
therapy (and if therapy longer than 7 days, not done at least every  
7 days). At least one drug level not done.
electrolyte/nutrient supplementation Drug induced imbalances Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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out routinely because of economic considerations, and clinicians 
mostly rely on clinical signs and symptoms to assess toxicity.
Morris and Cantril validated drug-related morbidity indi-
cators developed in the United States and United Kingdom, 
and studied differences between the two setups. They reported 
that indicators used in the USA lacked relevance to the UK. 
They attributed this to the difference in clinical practice and 
philosophical view points of professional practice. But they 
concluded that if suitable validation processes can be devel-
oped, indicators from one setup can act as a starting point for 
another setup.22 The current work used indicators reported 
from various studies and attempted to validate such indicators 
for the study setup. This exercise gave insight into the view-
points of health care professionals in the study center. The 
methodology of using specific triggers or indicators offers 
flexibility in using this system for a variety of health care 
systems. The indicators can be   modified suitably according to 
individual setup.7 Several institutions have used this approach 
in their setup and have reduced harm up to 50%. Even though 
this method itself may not result in improvement in prevention 
of adverse events concerned, it provides a good platform for 
any organization which attempts to reduce adverse events. 
Record review using indicators might provide a better chance 
of detecting ADEs compared with many other commonly 
Table 4 Indicators of lab investigation
Indicators Cause
Frequent ECG request  Drug induced arrhythmias 
Blood dyscrasias Concurrent use of trimethoprim/sulfamethoxazole and methotrexate. Use 
of carbamazepine, ticlopidine. WBC/platelets/CBC not done at least every 
4 weeks.
Major and/or minor hemorrhagic event, InR . 6, elevated APTT Use of IV heparin, warfarin. PTT not done at least every day.  
Use of aspirin/clopidogrel/warfarin.
Abnormal liver function tests or clinical jaundice Use of a statin without baseline monitoring of liver function and subsequent 
monitoring at 6 monthly intervals. Use of pioglitazone.  
No baseline and follow up LFTs for every month for first 8 months.
Abnormal LFT Drug induced (statins, pioglitazone, isoniazid, rifampicin, pyrazinamide). LFTs 
not done at baseline and follow up.
Hyponatremia and/or excessive water retention and/or  
syndrome of inappropriate antidiuretic hormone (SIADH)
Use of carbamazepine. electrolytes/CBC not done before therapy initiated, at 
least weekly during the first month of therapy, at least monthly during the next 
5 months of therapy, and at least every  6 months thereafter. Thyroxine use.
electrolyte imbalance K, na, Cl, Ca, K Drug induced (diuretics, ACe inhibitors, potassium supplements). no 
electrolyte monitoring at the frequency of 10 days to a few months.
elevated BUn, SCr Drug induced ARF
Raised serum creatinine Use of an oral/topical nSAID for more than 3 months without monitoring 
serum creatinine at least every 3 months. 
Repeated request for lab assessment of any parameter Drug induced
Abbreviations: eCG, electrocardiography; InR, international normalized ratio; APTT, activated partial thromboplastin time; LFTs, liver function tests; SIADH, syndrome of 
inappropriate antidiuretic hormone hypersecretion; BUn, blood urea nitrogen; SCr, serum creatinine; WBC, white blood cell count; CBC, complete blood count; IV, intravenous; 
PTT, partial thromboplastin time; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARF, acute renal failure; NSAID, nonsteroidal anti-inflammatory drug.
Table 5 Most used indicators
Indicators Cause No. of times indicator   
identified in the case 
review (100 cases)
Abrupt withdrawal of medication Any ADe 82
Repeated request for lab assessment of any parameter Drug induced 36
Use of antihistamines  Drug allergy 20
Skin rashes/angioedema/Steven Johnson syndrome/Ten Drug induced 18
emergency visit/admission Drug induced complications 18
electrolyte imbalance K, na, Cl, Ca, K Drug induced (diuretics, ACe inhibitors, potassium  
supplements). no electrolyte monitoring  
at the frequency of 10 days to a few months.
16
electrolyte/nutrient supplementation Drug induced imbalances  12
Dose reduction Related to ADe 10
Frequent ECG request  Drug induced arrhythmias  8
Vomiting, nausea/use of antiemetics Drug induced  8
Abbreviations: Ten, toxic epidermal necrolysis; eCG, electrocardiography; ADe, adverse drug event; ACe, angiotensin converting enzyme.Drug, Healthcare and Patient Safety
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used methods like voluntary reporting, intensive monitor-
ing, and reporting of summary data. Use of this technique is 
also more economical when compared to other approaches. 
There are few limitations in this study which need to be 
considered. Even though indicators developed for one setup 
could be adopted for another setup, indicators adopted from 
a predominantly Western setup may not have relevance in the 
Indian setting. Unless the indicators are assessed by using 
them in the record review, the list might not reflect the useful 
indicators relevant for the current setup. Further validation is 
needed for this indicator list by actually using it for adverse 
event screening from the medical records.
Conclusion
The current work resulted in the development of an indicator list 
for identification of adverse events in the current setup. The list 
was prepared using the expert review and Delphi panel review. 
The final list contained a total of 49 indicators. The relevance 
of this indicator list was demonstrated by the presence of these 
indicators in the previously documented ADE case reports. 
This is the first study from India to report on the development 
of indicators, and this might provide an alternative method to 
detect ADEs in the studied health care setting.
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